Blood-derived ratio indexes associated with severity and prognosis of immune checkpoint inhibitor-related cardiotoxicity: a retrospective analysis
Authors:
Open Access
- 9 October 2025
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1676806
Abstract
Background: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune checkpoint inhibitor-related cardiotoxicities (iRCs). Blood-derived inflammatory ratios may serve as practical prognostic tools for these life-threatening complications.Methods: We conducted a retrospective study of 105 iRC patients treated with ICIs between 2020 and 2023. Patients were classified by Common Terminology Criteria for Adverse Events (CTCAE) severity grades. We identified the most important blood-derived ratio indexes at iRC diagnosis associated with the severity of iRCs, 40-day major adverse cardiovascular events (MACEs), and long-term mortality using receiver operating characteristic (ROC) analyses and restricted cubic spline (RCS) curves. Kaplan–Meier survival curves, Cox regression, and subgroup analysis were also performed to evaluate them.Results: High-grade iRCs patients (n=40) showed a significantly higher system inflammation response index (SIRI) (8.21 vs. 2.21, p3.07 was strongly associated with 40-day MACEs [hazard ratios (HR)=6.56, p7.88 was associated with increased long-term mortality risk (HR = 2.33, p=0.003). Both SIRI and NLR remained significant after adjusting for cardiac biomarkers and clinical variables and were found associated with iRC severity-related cardiac biomarkers.Conclusion: SIRI and NLR are effectively associated with iRC severity and could stratify the risk of developing poor short- and long-term prognoses. These readily available inflammatory indexes could improve risk assessment and guide clinical decision-making for iRC patients. However, further prospective studies should validate their utility in diverse populations.Keywords
This publication has 38 references indexed in Scilit:
- Prognostic value of systemic inflammation response index in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors: a meta-analysisAnnals of Medicine, 2024
- Nomograms based on ratio indexes to predict severity and prognosis in immune checkpoint inhibitors-related myocarditis: a retrospective analysisJournal of Cancer Research and Clinical Oncology, 2024
- High neutrophil-to-lymphocyte ratio is associated with cancer therapy-related cardiovascular toxicity in high-risk cancer patients under immune checkpoint inhibitor therapyClinical Research in Cardiology, 2023
- Inflammatory Biomarkers in Assessing Severity and Prognosis of Immune Checkpoint Inhibitor-Associated CardiotoxicityESC Heart Failure, 2023
- Phenotypes, roles, and modulation of regulatory lymphocytes in periodontitis and its associated systemic diseasesJournal of Leukocyte Biology, 2021
- Immune Checkpoint Inhibitor‐Based Strategies for Synergistic Cancer TherapyAdvanced Healthcare Materials, 2021
- Immune regulation by monocytesSeminars in Immunology, 2018
- Neutrophil extracellular traps in immunity and diseaseNature Reviews Immunology, 2017
- Fulminant Myocarditis with Combination Immune Checkpoint BlockadeNew England Journal of Medicine, 2016
- Endothelial expression of PD‐L1 and PD‐L2 down‐regulates CD8+ T cell activation and cytolysisEuropean Journal of Immunology, 2003